Navigation Links
Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
Date:10/24/2008

EAST BRUNSWICK, N.J., Oct. 24 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today that the company will release financial results for the third quarter 2008 following the close of the market on Wednesday, November 5, 2008.

Christopher Clement, President and Chief Executive Officer and Brian Hayden, Senior Vice President and Chief Financial Officer will host an investment community conference call beginning at 10:00 a.m. Eastern Time on November 6, 2008 to discuss these results and to answer questions.

Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of Savient Pharmaceuticals' web site at http://www.savient.com. To listen to the live call, please go to the web site fifteen minutes prior to its start to register, download, and install the necessary audio software.

A replay will be available on the web site. A telephone replay will be available from 12:00 p.m. Eastern Time on November 6, 2008 through 11:59 p.m. Eastern Time on November 20, 2008 by dialing (800) 642-1687 (domestic) or (706) 645-9291 (international) and entering conference ID number 67897749.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets. The company's product development candidate, Puricase(R) (pegloticase) for treatment-failure gout, has reported positive Phase 1, 2 and 3 clinical data. Patient dosing in the Phase 3 clinical studies began in June 2006; patient enrollment was completed in March 2007; and the
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... October 18, 2014 The Biomass ... in the five years to 2014. The industry's expansion ... energy tax credits that encouraged the use of biomass ... portfolio standards (RPSs), which require local utilities to generate ... total energy portfolio. Increased campaigning for green technology also ...
(Date:10/18/2014)... 2014 The report " Cloud ... Text; Web; Speech; Machine; Video; Predictive Analytics: Global ... Forecasts & Analysis (2013 - 2018) ", defines ... various sub segments with an in-depth analysis and ... the factors driving this market, various restraints, and ...
(Date:10/17/2014)... received a $451,781 Air Force Office of Scientific Research ... and nano-scale level that will provide clues for predicting ... and Aerospace Engineering, said the new technology and process ... of an aircraft,s wing., "We,ll be able to determine ... at it on this scale," Huang said. "Certain patterns ...
(Date:10/17/2014)... and HILDEN, Germany ...   , Translational research in cancer ... being presented at the American Society of Human ... 250,000-plus DNA samples linked to Ingenuity ®  Knowledge ... for genomic analysis  Ingenuity ®  Variant ...
Breaking Biology Technology:Biomass Power in the US Industry Market Research Report from IBISWorld Has Been Updated 2Biomass Power in the US Industry Market Research Report from IBISWorld Has Been Updated 3Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 2Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 3Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 4Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 5UT Arlington project to detect possible damages in aircraft parts early in process 2QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 2QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 3QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 4QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 5QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 6
... for Food and Other Packaging Uses, MELBOURNE, ... DD ) and Plantic Technologies Limited, an ... to,collaborate in the development and sale of renewably ... the collaborative development of new, renewably sourced,resins and ...
... Inc.,(Nasdaq: MITI ), a biopharmaceutical company focusing ... cancer, inflammation and,autoimmune diseases, today announced that Dr. ... will present at the Sachs Associates,7th Annual Biotech ... October 2, 2007 at 12:00 noon central European ...
... PALO ALTO, Calif., Sept. 26 Avicena Group,Inc. ... that,develops central nervous system therapeutics for neurodegenerative,diseases, announced ... of its,private offering of Preferred Stock and warrants. ... and in exchange sold,3,110 shares of newly designated ...
Cached Biology Technology:DuPont and Plantic Technologies Announce Starch-Based Bio Materials Collaboration 2DuPont and Plantic Technologies Announce Starch-Based Bio Materials Collaboration 3Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum 2Avicena Group Announces Closing of Private Offering 2
(Date:10/18/2014)... group of 2,000 patients referred for evaluation of ... molecular diagnosis for 25 percent, including detection of ... mutations contributing to disease, according to a study ... being released to coincide with the American Society ... analyzes the exons or coding regions of thousands ...
(Date:10/17/2014)... German . Why ... order to reproduce? And why are there two sexes anyway? ... issue of the research journal Molecular Human Reproduction ... from Bielefeld University Bielefeld has compiled this special issue on ... female to copulate with several males in quick succession – ...
(Date:10/16/2014)... body. Battles are won, lost or sometimes end ... as tumor dormancy—can last up to 25 years ... poorly understood. , A new computational model ... Professor of Chemistry at Princeton University, may help ... switch to a malignant state. Published today in ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Sperm wars 2Modeling tumor dormancy 2
... is available in Spanish . , Adolescents of ... and regular physical activity present increased levels of insulin and ... appetite control and energy expenditure. This was the conclusion drawn ... of the University of Granada . Further, after thorough ...
... of diabetes risk than does BMI. This is the ... the German Institute for Nutritional Research in Potsdam-Rehbrcke, in ... (Dtsch Arztebl Int 2010; 107[26]: 470-6). Current guidelines ... overweight should be based on the determination of the ...
... Minimally invasive surgery is increasingly common and effective for ... which use slender, handheld tools inserted into the body ... the most important factor determining the success of the ... Polytechnic Institute has won a $2.3 million federal grant ...
Cached Biology News:Children in good shape have better appetite control and energy expenditure 2Designing touch-sensitive virtual reality tools to train and test tomorrow's surgeons 2Designing touch-sensitive virtual reality tools to train and test tomorrow's surgeons 3